Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2018-08-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于调整公司非公开发行股票方案的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding adjustments to its non-public issuance of shares plan. It details changes in the pricing and subscription terms of the non-public stock issuance, references board and shareholder meetings approving the plan, and mentions the need for approval from the China Securities Regulatory Commission. The content focuses on the specifics of a capital raising activity through non-public stock issuance, including pricing, subscription limits, and procedural approvals. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2018-08-16 Chinese
第二期员工持股计划（草案）摘要（非公开发行方式认购）（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "第2 期员工持股计划（草案）摘要（修订稿）" which translates to "2nd Employee Stock Ownership Plan (Draft) Summary (Revised)". It details the purpose, principles, participants, funding, stock source, pricing, management, rights, obligations, and procedures related to an employee stock ownership plan. It references legal and regulatory frameworks such as the Company Law, Securities Law, and China Securities Regulatory Commission (CSRC) approvals. The document is comprehensive and over 12,000 characters, indicating it is a substantive plan document rather than a brief announcement. It is not a financial report, earnings release, or regulatory filing but a detailed plan related to employee stock ownership and non-public stock issuance. This fits best under the category of Capital/Financing Update (CAP), as it concerns company fundraising and capital structure changes through a non-public stock issuance to employees under an employee stock ownership plan.
2018-08-16 Chinese
2018年非公开发行股票方案的论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "2018 年非公开发行股票方案的论证分析报告（修订稿）" which translates to "2018 Non-public Stock Issuance Plan Demonstration and Analysis Report (Revised)". It discusses the company's plan for a non-public issuance of shares, including the background, purpose, issuance details, pricing, legal compliance, and fairness of the issuance. The content focuses on capital raising through equity issuance, the use of proceeds, and regulatory compliance related to the issuance. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. Instead, it is a detailed update on the company's capital raising activity and financing plans. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (11,598 characters) and detailed content support this classification with high confidence.
2018-08-16 Chinese
关于非公开发行股票预案修订情况说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding revisions to a non-public stock issuance plan by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details changes in the issuance price, subscription amounts, and related approvals. The content focuses on capital raising activities and adjustments to the financing plan rather than presenting financial statements or full reports. The document length is short (1785 characters) and it is clearly an update on financing activities, not a full report or regulatory certification. Therefore, it fits best under Capital/Financing Update (CAP).
2018-08-16 Chinese
关于注射用重组人生长激素新增适应症申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Anhui Anke Biotechnology (Group) Co., Ltd. regarding the approval of new indications for their recombinant human growth hormone product by the National Medical Products Administration (China's drug regulatory authority). It details the regulatory approval of additional uses for an existing drug product. The document is short (1037 characters) and serves as an official announcement of regulatory approval rather than a detailed financial report or presentation. It does not contain financial statements, management discussion, or detailed investor information. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about product approval and related risks, which does not fit other more specific categories like Annual Report, Earnings Release, or Capital Update.
2018-07-30 Chinese
关于收到《中国证监会行政许可项目审查一次反馈意见通知书》的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding receipt of a feedback notice from the China Securities Regulatory Commission (CSRC) about their administrative licensing project review for a non-public issuance of new shares. It states the company must respond within 30 working days and that the approval is uncertain. The document is short (648 characters) and serves as a regulatory update on the status of a capital raising approval process, not the actual financing report or detailed financial data. This fits the category of Capital/Financing Update (CAP) as it relates to company fundraising activities and regulatory review status.
2018-07-26 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.